Romidepsin is clinically approved for the treatment of cutaneous T-cell lymphoma and other peripheral T-cell lymphomas, and is highly selective for binding class I subtypes as compared to the other HDAC classes [20,21]. The gene discussed is HDAC9; the disease is peripheral T-cell lymphoma, not otherwise specified.